Disruption of histone acetylation patterns is a common feature of cancer cells, but very little
is known about its genetic basis. We have identified truncating mutations in one of the …

Histone deacetylase inhibitors (HDACi) represent a new group of drugs currently being
tested in a wide variety of clinical applications. They are especially effective in preclinical …

Histone deacetylase inhibitors (HDACi) are in clinical trials against a variety of cancers.
Despite early successes, results against the more common solid tumors have been mixed …

Inappropriate transcriptional repression involving histone deacetylases (HDACs) is a
prominent cause for the development of leukemia. We now identify faulty expression of a …

Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and
apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in …

Purpose: Recently, several studies reported a strong functional link between histone
deacetylases (HDAC) and the development of tumors of the large intestine. However …

In recent years it has become widely recognized that histone modification plays a pivotal
role in controlling gene expression and is involved in a wide spectrum of disease regulation …

Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene
expression, DNA repair, and stress response. These processes often are altered in tumors …

The epigenome is defined by DNA methylation patterns and the associated posttranslational
modifications of histones. This histone code determines the expression status of individual …

Histone deacetylases (HDACs) modify core histones and participate in large regulatory
complexes that both suppress and enhance transcription. Recent studies indicate that some …